Company profile: ChromoTek
1.1 - Company Overview
Company description
- Provider of immunologic research and detection reagents and tools for proteomics and cell biology, offering Nanobody-based Nano-Traps for immunoprecipitation; Chromobodies for real-time, live-cell imaging; Nano-Secondary reagents for higher-resolution imaging with minimal label displacement; Nano-Boosters & Nano-Labels for microscopy; Nano-Caps for one-step protein purification; and Nano-CaptureLigands for site-directed antibody immobilization.
Products and services
- Nano-Traps: Ready-to-use affinity beads engineered with Nanobodies coupled to various resins for immunoprecipitation, enabling efficient protein pulldown
- Chromobodies: Fluorescent nanoprobes genetically fused to a fluorescent protein for real-time and live-cell imaging of intracellular endogenous proteins
- Nano-Secondary reagents: Recombinant alpaca single domain VHHs conjugated to fluorescent dyes for higher resolution imaging with minimal label displacement
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to ChromoTek
Vicam
HQ: United States
Website
- Description: Provider of testing solutions to detect mycotoxins in raw materials, grains, and feeds; aflatoxins in food and feed products; Bisphenol A (BPA) in consumer products; citrinin in food and feed; deoxynivalenol (DON) in grains and feeds; and fumonisins in corn, to prevent contamination, ensure safety, and comply with safety regulations.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vicam company profile →
Fantex
HQ: United Kingdom
Website
- Description: Provider of polymeric biocide technology designed to combat bacteria and infectious diseases. Fantex technology represents a new generation and class of biocides that exploit natural bio-defence-mimetics and work differently from chemical biocides by using a novel method of bacterial cell killing.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Fantex company profile →
Advicenne
HQ: France
Website
- Description: Provider of specialty pharmaceutical treatments targeting rare kidney diseases, developing and commercializing therapies in nephrology. Portfolio includes Sibnayal for distal renal tubular acidosis (dRTA); licensed medications Likozam (clobazam) and Levidcen (levetiracetam) in France; and ADV7103, an experimental late-stage therapy for dRTA and cystinuria in children and adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Advicenne company profile →
Zeptosens
HQ: Switzerland
Website
- Description: Provider of ultra-sensitive microarray platforms for quantitative proteomic investigations, delivering sensitive, quantitative protein profiling and signaling pathway analysis via reverse protein arrays. Products include ZeptoREADER, a microarray reader for planar waveguide technology, and ZeptoMARK.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Zeptosens company profile →
Reveal Biosciences
HQ: United States
Website
- Description: Provider of computational pathology diagnostics using AI to analyze large whole slide microscope images, combining a histopathology laboratory with machine learning to diagnose disease. Offers a new class of diagnostics with fundamental improvements in reach, cost, speed, accuracy, and scale in disease diagnosis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Reveal Biosciences company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for ChromoTek
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to ChromoTek
2.2 - Growth funds investing in similar companies to ChromoTek
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for ChromoTek
4.2 - Public trading comparable groups for ChromoTek
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →